Objective: Patch pumps, i.e. tubeless insulin pumps, are an attractive alternative to conventional insulin pumps for people with type 1 diabetes and type 2 diabetes on insulin therapy. However, to date, the patient-related benefits of patch pumps are not well understood. Methods: A systematic review was conducted to summarize potential patient-relevant advantages and disadvantages of patch pumps and to assess relevant studies on patient-reported outcomes (PROs) . Relevant studies were identified by a systematic PubMed search. In addition, the reference lists of the respective articles and Google Scholar were checked for further references. English-language articles published before June 30, 2021, were included; no other publication date criteria were specified. Results: A total of 12 studies were included. The results of this analysis demonstrate that patch pumps improve quality of life, reduce diabetes-related symptoms, increase patient satisfaction, and are preferred by patients compared with conventional insulin pumps and daily multiple injection (MDI) therapy. However, several methodological limitations of the identified studies limit the power of this analysis. Conclusions: Despite the limited number of studies evaluating the benefits of patch pumps in relation to PROs, there is increasing evidence that people with diabetes prefer patch pumps compared to MDI and conventional pumps. It is notable that this aspect has been relatively understudied. More systematic studies evaluating the benefit of patch pumps in relation to PROs are needed. Disclosure B.Kulzer: Advisory Panel; Bayer AG, Bayer AG, Becton, Dickinson and Company, Becton, Dickinson and Company, Berlin-Chemie AG, Berlin-Chemie AG, Dexcom, Inc., Dexcom, Inc., Insulet Corporation, Novo Nordisk, Roche Diabetes Care, Sanofi, Sanofi-Aventis Deutschland GmbH, Research Support; Novo Nordisk, Roche Diabetes Care. G.Freckmann: Advisory Panel; Abbott Diabetes, Dexcom, Inc., Lilly, Roche Diabetes Care, Roche Diagnostics, Consultant; Ascensia Diabetes Care, Berlin-Chemie AG, Boydsens, Metronom, mySugr, Roche Diabetes Care, Sanofi-Aventis Deutschland GmbH, Research Support; Dexcom, Inc., Medtronic, Menarini Group, Roche Diabetes Care, Sanofi, Speaker's Bureau; Berlin-Chemie AG, Dexcom, Inc., Lilly, Novo Nordisk, Roche Diabetes Care, Terumo Corporation. L.Heinemann: Board Member; Lifecare, Inc., Consultant; Becton, Dickinson and Company, Roche Diabetes Care, Stock/Shareholder; Profil Institut für Stoffwechselforschung GmbH, Science Consulting in Diabetes GmbH. O.Schnell: Advisory Panel; AstraZeneca, Boehringer Ingelheim International GmbH, Lilly, Roche Diabetes Care. R.Hinzmann: Employee; Roche Diabetes Care. R.Ziegler: Advisory Panel; Eli Lilly and Company, mySugr, Novo Nordisk, Roche Diabetes Care, Speaker's Bureau; A. Menarini Diagnostics, Abbott Diabetes, Dexcom, Inc., Eli Lilly and Company, Glooko, Inc., Novo Nordisk, Roche Diabetes Care.

中文翻译：

---

1495-PUB：胰岛素贴片泵：糖尿病患者是否有与患者相关的优势？

目的：贴片泵，即无内胎胰岛素泵，对于接受胰岛素治疗的 1 型糖尿病和 2 型糖尿病患者来说，是一种有吸引力的替代传统胰岛素泵的方法。然而，迄今为止，贴片泵与患者相关的益处尚不清楚。方法：进行系统评价以总结贴片泵与患者相关的潜在优势和劣势，并评估有关患者报告结果 (PROs) 的相关研究。通过系统的 PubMed 搜索确定了相关研究。此外，还检查了相应文章和 Google Scholar 的参考文献列表以获取进一步参考。包括在 2021 年 6 月 30 日之前发表的英文文章；没有指定其他出版日期标准。结果：共纳入 12 项研究。该分析结果表明，贴片泵可改善生活质量、减少糖尿病相关症状、提高患者满意度，与传统胰岛素泵和每日多次注射 (MDI) 治疗相比，更受患者青睐。然而，已确定研究的若干方法学限制限制了该分析的能力。结论：尽管评估贴片泵与 PRO 相关益处的研究数量有限，但越来越多的证据表明，与 MDI 和传统泵相比，糖尿病患者更喜欢贴片泵。值得注意的是，这方面的研究相对不足。需要更系统的研究评估贴片泵与 PRO 相关的益处。披露 B.Kulzer：咨询小组；拜耳公司、拜耳公司、Becton、Dickinson and Company、Becton、Dickinson and Company, Berlin-Chemie AG, Berlin-Chemie AG, Dexcom, Inc., Dexcom, Inc., Insulet Corporation, Novo Nordisk, Roche Diabetes Care, Sanofi, Sanofi-Aventis Deutschland GmbH, Research Support；诺和诺德，罗氏糖尿病护理。G.Freckmann：咨询小组；Abbott Diabetes, Dexcom, Inc., Lilly, Roche Diabetes Care, Roche Diagnostics, 顾问；Ascensia Diabetes Care, Berlin-Chemie AG, Boydsens, Metronom, mySugr, Roche Diabetes Care, Sanofi-Aventis Deutschland GmbH, 研究支持；Dexcom, Inc.、美敦力、美纳里尼集团、罗氏糖尿病护理、赛诺菲、发言人局；Berlin-Chemie AG、Dexcom, Inc.、礼来、诺和诺德、罗氏糖尿病护理、泰尔茂公司。L.Heinemann：董事会成员；Lifecare, Inc.，顾问；Becton, Dickinson and Company, Roche Diabetes Care, 股票/股东；Profil Institut für Stoffwechselforschung GmbH, 糖尿病有限公司的科学咨询。O.Schnell：咨询小组；阿斯利康、勃林格殷格翰国际有限公司、礼来、罗氏糖尿病护理。R.Hinzmann：员工；罗氏糖尿病护理。R.Ziegler：咨询小组；Eli Lilly and Company, mySugr, Novo Nordisk, Roche Diabetes Care, Speaker's Bureau；A. 美纳里尼诊断、雅培糖尿病、Dexcom, Inc.、礼来公司、Glooko, Inc.、诺和诺德、罗氏糖尿病护理。